John N Ratchford
Overview
Explore the profile of John N Ratchford including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
2006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marignier R, Pittock S, Paul F, Kim H, Bennett J, Weinshenker B, et al.
Mult Scler Relat Disord
. 2022 Feb;
57:103356.
PMID: 35158465
Background: The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive (AQP4+) or -seronegative (AQP4-)....
2.
Karnell J, Wu Y, Mittereder N, Smith M, Gunsior M, Yan L, et al.
Sci Transl Med
. 2021 May;
13(595).
PMID: 34039741
Plasmacytoid dendritic cells (pDCs) not only are specialized in their capacity to secrete large amounts of type I interferon (IFN) but also serve to enable both innate and adaptive immune...
3.
Marignier R, Bennett J, Kim H, Weinshenker B, Pittock S, Wingerchuk D, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Mar;
8(3).
PMID: 33771837
Objective: To assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody,...
4.
Cree B, Bennett J, Kim H, Weinshenker B, Pittock S, Wingerchuk D, et al.
Mult Scler
. 2021 Feb;
27(13):2052-2061.
PMID: 33538237
Background: In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. Objective: To demonstrate the robustness of...
5.
Cree B, Bennett J, Kim H, Weinshenker B, Pittock S, Wingerchuk D, et al.
Lancet
. 2019 Sep;
394(10206):1352-1363.
PMID: 31495497
Background: No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the...
6.
Beekman J, Keisler A, Pedraza O, Haramura M, Gianella-Borradori A, Katz E, et al.
Neurol Neuroimmunol Neuroinflamm
. 2019 Jul;
6(4):e580.
PMID: 31355316
Objective: To gain insights into NMOSD disease impact, which may negatively affect QoL of patients, their families, and social network. Methods: The current study used validated instruments to assess physical,...
7.
Rothman A, Murphy O, Fitzgerald K, Button J, Gordon-Lipkin E, Ratchford J, et al.
Ann Clin Transl Neurol
. 2019 Mar;
6(2):222-232.
PMID: 30847355
Objective: Optical coherence tomography (OCT)-derived measures of the retina correlate with disability and cortical gray matter atrophy in multiple sclerosis (MS); however, whether such measures predict long-term disability is unknown....
8.
Eaneff S, Wang V, Hanger M, Levy M, Mealy M, Brandt A, et al.
Mult Scler Relat Disord
. 2017 Oct;
17:116-122.
PMID: 29055439
Background: Few studies have evaluated patient perspectives on neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD). Objective: Describe patient-reported clinical and treatment experience in NMOSD and compare disease characteristics of...
9.
Cree B, Bennett J, Sheehan M, Cohen J, Hartung H, Aktas O, et al.
Mult Scler
. 2015 Dec;
22(7):862-72.
PMID: 26666258
Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported. Objective: To design a placebo-controlled study in NMO...
10.
Saidha S, Al-Louzi O, Ratchford J, Bhargava P, Oh J, Newsome S, et al.
Ann Neurol
. 2015 Jul;
78(5):801-13.
PMID: 26190464
Objective: The aim of this work was to determine whether atrophy of specific retinal layers and brain substructures are associated over time, in order to further validate the utility of...